An M142 HIMARS operated by the 7th ID/MDC-PAC launches a missile from Palawan, Philippines, during a live-fire exercise, Apr. 27, 2026. (Staff Sgt. Brandon Rickert/U.S. Army) HONOLULU — The U.S. Army ...

Novo Nordisk is gearing up to submit its rare blood disorder drug to the FDA after the former Forma Therapeutics asset reduced a painful complication of sickle cell disease (SCD) in a phase 3 study.

The LMP Capital and Income Fund (SCD) is a closed-end fund that aims to provide its investors with a high level of current income along with capital appreciation through investments in a portfolio ...

Fort Riley added nearly 250 soldiers and their families to the Flint Hills region Tuesday. Soldiers representing the 5th Engineer Battalion “patched over” to the 1st Infantry Division during a ...

Salesforce Inc. today released details about its thinking in acquiring Informatica Inc. despite that company’s apparent overlap with Salesforce’s MuleSoft integration subsidiary. Executives said the ...

Want to know more about Infantry Marines? Marine Infantry is one of the deadliest fighting forces the world has ever seen. With an extensive history on the battlefield, and a major component of a lot ...

Lian Li tick all the boxes again, with some adjustments to the original LANCOOL 217, resulting in great overall performance and fantastic looks. The Lian Li LANCOOL 217 has been a popular case among ...

Utah is gaining a new Infantry Battalion - the 1st Battalion, 204th Infantry Regiment - marking a significant step in the state’s military growth. Equipped with modern technology like the Infantry ...

Soldiers load into an Infantry Squad Vehicle during a live fire exercise in Grafenwoehr Training Area, Germany. (Kevin Sterling Payne/U.S. Army) Over the next two years, the U.S. Army will convert 25 ...

NOVO SELO TRAINING AREA, Bulgaria – Bright, incendiary trails erupted through the night, as the tracer rounds fired from M2A3 Bradley Infantry Fighting Vehicles advanced toward their targets. Soldiers ...

Pfizer’s sickle cell disease (SCD) drug has flunked a key phase 3 test, the latest blow to the pharma’s $5.4 billion acquisition of Global Blood Therapeutics. Pfizer acquired the P-selectin inhibitor, ...